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Abstract We previously identified a novel amyloid L-protein
(AL), that binds to GM1 ganglioside, in brains exhibiting the
early pathological changes of AD. In this study, we raised
monoclonal antibodies, using membrane fractions containing
abundant GM1 ganglioside-bound AL as antigens. Monoclonal
antibody 4396, produced in this study, immunoprecipitates AL42
in the membrane fractions of brains with diffuse plaques, but does
not react with soluble AL42 or GM1 ganglioside. Furthermore,
this antibody recognizes the AL bound to lipid vesicles containing
GM1 ganglioside, and unexpectedly, phosphatidylinositol. In
contrast, a control anti-AL monoclonal antibody does not
recognize the AL bound to these lipid vesicles. These results
indicate that AL associated with lipids has an immunoreactivity
distinct from that of soluble A.
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1. Introduction
The deposition of amyloid L-protein (AL), a proteolytic
cleavage product of L-amyloid precursor protein (LAPP) [1],
is an initial and invariable feature in the brains of subjects
with Alzheimer’s disease (AD). However, the molecular mech-
anism of this AL deposition remains unclear. To address this
issue, we previously fractionated cerebral cortices from AD
and Down’s syndrome subjects, and healthy aged individuals
using sucrose density gradient centrifugation, and searched for
the initially deposited AL species [2]. In that study, we found a
novel AL, with unique immunoreactivities, that tightly binds
to GM1 ganglioside in the brains of subjects in the early
stages of AD. Although AL is physiologically secreted into
the extracellular space and GM1 ganglioside is expressed on
the extracellular surface, particularly on synaptic membranes,
we were unable to ¢nd this GM1 ganglioside-bound AL
(GM1/AL) in the control cerebral cortices. Thus, we raised a
possibility that GM1/AL is generated intracellularly due to an
alteration in the membrane tra⁄c or an abnormal tra⁄cking
of AL in AD brains. However, immunohistochemical studies,
to date, have failed to demonstrate the intracellular deposition
of AL in the brains of subjects with AD, which suggests that
GM1/AL cannot be recognized by conventional antibodies
raised against synthetic AL. The aim of this study is to deter-
mine whether AL associated with lipid molecules including
GM1 ganglioside has an immunoreactivity distinct from those
of soluble and amyloid AL. We raised monoclonal antibodies
using membrane fractions containing GM1/AL as an antigen,
and investigated those immunoreactivities to the AL in the
membrane fractions from AD brains and to the AL bound
to lipid vesicles.
2. Materials and methods
2.1. Materials
The AL peptides (AL1-40, AL1-42) and GM1 ganglioside were ob-
tained from Bachem California Inc. Phosphatidylcholine (PC) was
obtained from Avanti Polar Lipids, and the mixed ganglioside
(MG) fraction of bovine brain and phosphatidylinositol (PI) were
obtained from Sigma. The antibodies used in this study were BC05
(speci¢c for AL42/43), BAN052 (raised against AL1-16), whose char-
acteristics have been described elsewhere [3,4], 4G8 (speci¢c for AL17-
24) (SENETECH) and an anti-human AL IgG (raised against AL8-17)
(clone 6F/3c, Dako). Control mouse IgM was obtained from Zymed
Laboratories, Inc.
2.2. Preparation of membrane fractions
To raise monoclonal antibodies against GM1/AL, membrane frac-
tions were prepared from the cerebral cortices (800 mg) of subjects
with abundant di¡use plaques using sucrose density gradient centrif-
ugation as described previously [2]. To partially purify the GM1/AL,
the membrane fractions, referred to as F1 in our previous paper [2],
were solubilized in Laemmli sample bu¡er containing 8 M urea and
then electrophoresed. Prepcell electrophoretic fractionation (Bio-Rad)
was employed to obtain GM1/AL. Prepcell electrophoresis fractions
were concentrated using the Microcon 3 concentrator (Amicon).
2.3. In vitro immunization and screening of hybridoma clones
In vitro immunization was performed as previously described [5,6].
Spleen cells from two mice (Balb/c, 6 weeks old, female) were sus-
pended in 45 ml of Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 20% fetal calf serum (FCS), 50 WM L-
mercaptoethanol, 20 Wg/ml N-acetylmuramyl-L-alanyl-D-isoglutamine
and plated onto a 24-well plate (0.45 ml/well, 4 wells). The cells were
incubated with the antigen (1.2 ng AL/well) at 37‡C and in 5% CO2
for 4 days. PA-1 myeloma cells (3U106) (a gift from T. Arai) and the
spleen cells (3U106) were gently mixed and placed in an electric fusion
apparatus (Shimadzu) following washing with 0.3 M sucrose. These
fused hybrid cells were then cultured in RPMI 1640 medium contain-
ing hypoxanthine-aminopterin-thymidine (HAT) in the feeder layer
for 10 to 14 days. To obtain positive clones, the supernatants of
hybridoma cell cultures were screened using the following two inde-
pendent procedures. In the ¢rst procedure, 100 Wl of the supernatants
was applied to the smear of the membrane fractions from brains with
abundant di¡use plaques, and immunoglobulins that bound to the
smeared membrane fractions were visualized using a vectastain
ABC-immunostaining kit (Vector Laboratories, Inc.). In the second
procedure, blots of the same membrane fractions as used in the ¢rst
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procedure, synthetic AL1-42 and puri¢ed GM1 ganglioside were im-
munoreacted with the supernatants. The blots were then incubated
with horseradish peroxidase-conjugated goat anti-mouse IgG or
IgM. The bound enzyme activities were visualized using an enhanced
chemiluminescence (ECL) detection system (Amersham, Buckingham-
shire, UK). The clones showing positive reactivities both in the smear
staining and in the immunoblotting of the membrane fractions, in
conjunction with negative reactivities in the immunoblotting of syn-
thetic AL1-42 and GM1 ganglioside, were selected. Subclass speci¢c
antisera were used to determine the immunoglobulin subtypes of the
monoclonal antibodies.
2.4. Puri¢cation of IgM monoclonal antibody
Isolated hybrid cell clones, which had been determined to generate
IgM monoclonal antibodies, were grown in the intraperitoneal space
of mice. Ascites £uid containing monoclonal antibodies was obtained
at 2^4 weeks after the injection of hybrid cell clones. The ascites £uid
(14 ml) was ¢ltered through a 0.45 Wm membrane, dialyzed against
2 mM phosphate bu¡er (PB), pH 6.0 for 18 h at 4‡C, and then
centrifuged at 12 000 rpm for 20 min. The pellets were washed with
PB and recentrifuged at 12 000 rpm for 20 min. The pellets were
resuspended in PB and then dialyzed against 10 mM PB containing
0.15 M NaCl, pH 7.4. Monoclonal antibody 4396 is one of the puri-
¢ed IgM antibodies through this process.
2.5. Immunoprecipitation of AL in the membrane fraction
The cerebral cortices exhibiting abundant di¡use plaques were frac-
tionated using sucrose density gradient centrifugation. The membrane
fractions (protein; 250^400 Wg) were sonicated in Tris-bu¡ered saline
containing 0.1% Tween 20 (TBS-T), pH 7.4 and immediately reacted
with 50 Wg of monoclonal antibody 4396, 50 Wg of control IgM, 1 Wg
of 4G8, or 0.5 Wg of BAN052 and incubated at 4‡C overnight. The
incubation mixtures were then centrifuged at 15 000 rpm for 15 min.
The pellets were washed with ice-cold TBS-T and solubilized in RIPA
bu¡er (50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5%
deoxycholic acid and 1.0% Nonidet P-40) at 4‡C for 30 min. The
solubilized mixtures were then centrifuged at 15 000 rpm for 15 min
and the supernatants were incubated with 20 Wl of protein G Sephar-
ose (PGS). In the case of incubation with IgM monoclonal antibody,
PGS which had been precoated with goat IgG fraction against mouse
IgM at 4‡C for 60 min was used. Finally, the PGS was repeatedly
washed with ice-cold Tris-bu¡ered saline. For control immunoprecip-
itation, 1 Wg of synthetic AL1-42 was suspended in RIPA bu¡er, and
incubated with the same antibodies as used for the immunprecipita-
tion of AL in the membrane fractions.
2.6. Western blotting
The PGS, following the incubation, was suspended in 25 Wl of
Laemmli sample bu¡er containing 8 M urea and boiled for 5 min.
The solubilized antigen-antibody complexes were then applied to a 4^
20% gradient Tris/tricine-SDS polyacrylamide gel (Multigel 4/20,
Daiichi Pure Chemicals Co., Ltd.). Western blotting was carried out
following the method of Ida et al. [7]. The separated proteins were
blotted onto nitrocellulose membranes at 380 mA for 45 min using a
semidry blotting apparatus. The blots were reacted with anti-AL
monoclonal antibodies (BC05, BAN052) after boiling in phosphate-
bu¡ered saline (8.1 mM disodium hydrogen phosphate, 1.5 mM po-
tassium dihydrogen phosphate, 137 mM sodium chloride and 2.7 mM
potassium chloride, pH 7.4) to enhance immunoreactivity. Reactive
AL on blots were visualized using the enhanced chemiluminescence
(ECL) system (Amersham, Buckinghamshire, UK).
2.7. Fluorescein labeling of the monoclonal antibody
The monoclonal antibody 4396 and anti-human AL IgG (6F/3c)
were labeled using 5(6) carboxy£uorescein-N-hydroxysuccinimide es-
ter (Boehringer, Mannheim) according to the manufacturer’s instruc-
tions. Fluorescently labeled antibodies were isolated by size exclusion
chromatography on a G25 column.
2.8. Preparation of the lipid vesicles
Lipid vesicles were prepared as previously described [8]. Brie£y, PC,
PI and MG fractions were dissolved in chloroform/methanol (1:1,
v/v). MG fractions were composed of predominantly GM1 ganglio-
side. All lipid aliquots were dried under a stream of nitrogen, lyophi-
lized overnight and suspended in phosphate-bu¡ered saline (PBS), pH
7.0. Lipid suspensions were subjected to 10 cycles of freeze-thawing in
an acetone:dry ice bath. Small unilamellar vesicles were obtained by
the sonication of the lipid suspensions for 20 min in a bath sonicator
(Branson Ultrasonic Corp.). Pure gangliosides do not form stable
vesicles and thus they were mixed with PC for vesicle formation.
2.9. Sucrose density gradient centrifugation
Samples contained 1000 Wg of lipid vesicles (PC, MG/PC, PI) and
V2 Wg of the £uorescein-labeled monoclonal antibody 4396, and,
when present, the synthetic AL peptide (AL1-40 and AL1-42) content
was 50 Wg in PBS; the total volume of samples was 150 Wl. Samples
were layered onto a step gradient of 10^40% sucrose and centrifuged
for 18 h at 35 000 rpm and 4‡C. Following centrifugation, the samples
were fractionated into 23 fractions. Each fraction was analyzed for
£uorescein £uorescence and for phosphorous content using the
Bartlett assay [9], to determine the presence of antibodies and lipid
vesicles, respectively.
3. Results
3.1. Screening of monoclonal antibodies
Membranous structures (Fig. 1a) and a band with apparent
molecular weight of 4 kDa (Fig. 1b) were immunoreacted with
the media of positive clones. The two positive clones, obtained
to date, were injected intraperitoneally using two Balb/c mice
to produce antibody-rich ascites £uid. The class of antibodies,
produced by both clones, was determined to be IgM using
Western blotting. Monoclonal antibody 4396 was one of the
puri¢ed IgM antibodies.
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Fig. 1. Screening of hybridomas using smear immunostaining and
Western blotting. a: Smear staining. Small aliquots of the mem-
brane fractions of cerebral cortices with abundant di¡use plaques
were smeared on glass slides and reacted with the supernatants of
cultures of hybridomas. The bound immunoglobulins were visual-
ized with the ABC-immunostaining kit. Membranous structures
were reacted with the supernatants of positive hybridomas. Original
magni¢cation, 200U. b: Western blotting. The blots of the same
membrane fractions as used in a. Synthetic AL42 and puri¢ed GM1
ganglioside were reacted with the supernatants of cultures of hybrid-
omas. The blots were then incubated with horseradish peroxidase-
conjugated goat anti-mouse IgG or IgM. The bound enzyme activ-
ities were visualized by use of an enhanced chemiluminescence
(ECL) detection system. The ALs in the membrane fractions were
recognized by IgM immunoglobulin in the supernatants of positive
hybridomas (arrow). Note that neither synthetic AL1-42 nor puri¢ed
GM1 ganglioside was recognized by the antibody.
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3.2. Immunoprecipitation of AL in the membrane fractions
AL in the membrane fractions was readily immunoprecipi-
tated with monoclonal antibody 4396 (Fig. 2). AL on the blots
of the immunoprecipitates was recognized by BC05 and
BAN052, which indicates that this AL species is AL1-42.
This result agrees with our previous ¢nding [2]. Monoclonal
antibody 4396 does not immunoprecipitate synthetic AL1-42,
whereas BAN052 and 4G8 immunoprecipitate AL in the
membrane fraction as well as synthetic AL1-42 (Fig. 2). One
possible explanation for the result shown in Fig. 2 is that
BAN052 and 4G8 recognize the contaminating AL in the
membrane fractions from soluble and/or amyloid core frac-
tions. Control IgM does not immunoprecipitate AL in the
membrane fractions or synthetic AL1-42 (data not shown).
Thus, the present results indicate that the monoclonal anti-
body 4396 is a highly unique antibody that speci¢cally recog-
nizes AL in the membrane fractions.
3.3. Recovery of £uorescein-labeled monoclonal antibody 4396
in sucrose density gradient centrifugation
Preincubation of £uorescently labeled monoclonal 4396
with AL1-40/lipid vesicle or AL1-42/lipid vesicle were sepa-
rated by sucrose density gradient centrifugation in a 10^40%
discontinuous sucrose gradient to distinguish free and bound
IgM. The reactivity of monoclonal antibody 4396 was found
toward AL1-40 and AL1-42 which were bound to lipid vesicles
containing GM1 ganglioside; however, these AL peptides
were not recognized by control anti-AL antibody (Dako
IgG) (Table 1). Furthermore, unexpectedly, AL peptides
bound to PI vesicles were also recognized by monoclonal anti-
body 4396, while these AL peptides were again undetected by
control anti-AL antibody (Table 1).
4. Discussion
Several lines of evidence indicate that the abnormal gener-
ation of AL due to altered processing of LAPP is a fundamen-
tal step in the initiation of AD. The cellular site(s) of AL
generation, however, still remain(s) to be identi¢ed. Previous
studies have revealed that AL is generated in acidic intracel-
lular organelles such as endosomes following the internaliza-
tion of LAPP [10,11], and it was recently reported that AL is
generated in the endoplasmic reticulum [12^14]. Although AL
has been detected in cell lysates following solubilization with
detergents [12,14^19], previous immunocytochemical studies
have failed to detect intracellular AL in situ. The reasons
for this failure are assumed to be as follows. First, AL secre-
tion may be so rapid that it cannot be easily detected. Second
and more likely, AL, in or associated with intracellular organ-
elles, may exhibit immunoreactivity distinct from that of solu-
ble AL. In this context, it must be noted that the amino-ter-
minal portion of AL exhibits various secondary structures
including random coils, K-helices and L-sheets, depending on
the solution conditions [20^25]: The amount of L-sheet struc-
ture increases in membrane-mimicking solvents [22]. Since
most of the antibodies to AL have been raised against syn-
thetic AL fragments, which are soluble in water, AL associated
with the membrane lipids is most likely not detected using
these conventional antibodies.
For the ¢rst time, our results clearly indicate that the AL
associated with membrane lipids possesses immunoreactivity
distinct from that of soluble AL. This is important to note
when addressing the physiological intracellular tra⁄cking of
AL, or when considering the possibility of abnormal intracel-
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Table 1
Relative extents of the binding of anti-AL antibodies to di¡erent vesicle preparations
Percentage of £uorescein-labeled anti-AL antibody associated with vesiclea
Anti-AL antibody 4396 Dako IgG
vesicle type vesicle alone vesicle+ AL1-40 vesicle+ AL1-42 vesicle alone vesicle+ AL1-40 vesicle+ AL1-42
PC 0 n.d.b n.d. 0 n.d. n.d.
MG/PC 0 2.1 1.9 0 0 0
PI 0.2 18.6 29.7 0 0 0
aSamples were layered onto a 10^40% sucrose gradient and centrifuged for 18 h at 35 000 rpm and 4‡C. After centrifugation, samples were
fractionated into 23 fractions. Each fraction was analyzed for £uorescein £uorescence and for phospholipid using the Bartlett assay. The percentage
of antibody associated with vesicle was determined using the following formula: % association = {(sum of £uorescence intensities of phospholipid-
containing fractions)/(sum of £uorescence intensities of all fractions)}U100(%).
bn.d., not determined. AL1-40 and AL1-42 do not bind to PC vesicles (McLaurin and Chakrabartty, unpublished data).
PC, phosphatidylcholine; MG, mixed ganglioside; PI, phosphatidylinositol.
Fig. 2. Immunoprecipitation of AL in the membrane fractions and
synthetic AL. Five hundred micrograms of the membrane fractions
of cerebral cortices exhibiting abundant di¡use plaques and 1 Wg of
synthetic AL1-42 were incubated with 0.5 Wg of BAN052, 1 Wg of
4G8, 50 Wg of monoclonal antibody 4396 and 50 Wg of control
IgM. The imunoglobulins were precipitated with protein G Sephar-
ose directly or following precoating with goat anti-mouse IgM anti-
serum. The immunoprecipitates were blotted and reacted with BC05
or BAN052. Note that monoclonal antibody 4396 only reacts with
AL in the membrane fractions.
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lular accumulation of AL in the brains of subjects with AD.
Monoclonal antibody 4396 was produced using membrane
fractions of brains exhibiting the early pathological changes
of AD, which were supposed to contain abundant GM1 gan-
glioside-bound AL1-42 [2]. However, in this study, the mono-
clonal antibody recognized both AL1-40 and AL1-42, which
had been associated with MG/PC and PI vesicles. Thus, it is
reasonable to conclude the following. First, a novel confor-
mation that AL adopts via association with lipid vesicles is
shared by AL1-40 and AL1-42. Second, GM1 ganglioside is
most likely to be the lipid molecule which binds to AL in the
brains of subjects with AD since GM1/AL was indeed de-
tected in our previous study [2]; however, the conformational
transition of AL caused by GM1 binding can be also induced
via interaction with other lipid molecules. Currently, we have
no explanation as to why monoclonal antibody 4396 exhibits
greater binding a⁄nity for AL bound to PI vesicles than for
AL bound to MG/PC vesicles. In a previous study [26], it was
reported that AL binds to acidic phospholipid via purely elec-
trostatic interaction. Thus, this kind of interaction might
cause a more dramatic alteration in the AL secondary struc-
ture than nonelectrostatic interaction between AL and gan-
glioside. In this context, it is noteworthy that PI is likely to
be the most e⁄cient inducer of L-structure in AL in phospho-
lipids examined so far [27], although the speci¢c secondary
structure of AL recognized by monoclonal antibody 4396 re-
mains to be determined. Recently, the binding of GM1 gan-
glioside to AL was con¢rmed in vitro [8,28,29]. Important
points from these studies are (a) GM1/AL adopts a novel
secondary structure as was determined by circular dichroism
spectroscopy [8,28] ; (b) GM1/AL causes membrane disruption
[8] and (c) GM1/AL accelerates the rate of amyloid ¢bril for-
mation [29]. The newly produced monoclonal antibodies in
this study may be useful probes to gain new insight into the
initial molecular mechanism of AL deposition, including the
generation of GM1/AL, in the brains of subjects with AD.
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